Sarah Tomassetti, MD
Investigator, The Lundquist Institute
Assistant Professor of Medicine, David Geffen School of Medicine at UCLA
Division of Hematology and Oncology, Department of Medicine, Harbor-UCLA Medical Center
Research DescriptionDr. Sarah Tomassetti is a hematologist and oncologist subspecializing in the treatment of hematologic malignancies, including lymphoma, leukemia, and multiple myeloma, as well as benign hematologic conditions. Dr. Tomassetti received her undergraduate degree in Molecular, Cellular, and Developmental Biology from the University of Colorado at Boulder and medical degree from the University of Southern California Keck School of Medicine. She stayed at the University of Southern California for her internal medicine residency training. Afterwards, she completed her fellowship in Hematology and Oncology at Harbor-UCLA.
Dr. Tomassetti is a Principal Investigator in clinical trials and is the Clinical Trial Lead in Hematology at Harbor-UCLA focusing on the treatment of hematologic malignancies. She is an Associate Program Director for the Harbor-UCLA Hematology/Oncology fellowship program and mentors medical students, residents, and fellows in research projects. She is on the steering committee for the Los Angeles Lymphoma Rounds as part of the Lymphoma Research Foundation. She is a member of the American Society of Hematology and American Society of Clinical Oncology.
- MD, 2013, Keck School of Medicine of the University of Southern California
Recent and/or Significant Publications
Pullarkat V, Zhuo M, Donohue VN, Tomassetti SE, Kirshnan A, Bhatia R, Forman SJ, Synold T. Iron chelators induce autophagic cell death in multiple myeloma cells. American Journal of Hematology. 2014 Aug;38(8):988-996.
Chen R, Palmer J, Tomassetti S, Popplewell L, Alluin J, Chomchan P, Nademanee A, Sidiqi T, Tsai N, Chen L, Zuo F, Abary R, Cai J, Herrera AF, Rossi JJ, Rosen ST, Forman SJ, Kwak LQ, and Holmberg L. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. Journal of Hematologic Oncology. 2018;11:87.
Sarah Tomassetti and Alex F. Herrera. Update on the role of brentuximab vedotin in classical Hodgkin lymphoma. Therapeutic Advances in Hematology. 2018;9(9):261-272.
Sarah Tomassetti and Robert Chen. The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma. Therapeutic Advances in Hematology. 2019;10.
Merryman RW, Carreau NA, Advani RH, Spinner MA, Herrera AF, Chen R, Tomassetti S, Ramchan-ren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David KA, Wei C, Lansigan F, Emery L, Persky D, Smith SM, Godfrey J, Chavez J, Cohen JB, Troxel AB, Diefenbach C, and Armand P. Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. The Oncologist.